A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2011
11/08/2011	CA2476430C Sodium channel blockers
11/08/2011	CA2443105C Functional role for cannabinoids in autonomic stability during sleep
11/08/2011	CA2442182C Modulation of pd-1 interactions with its ligands
11/08/2011	CA2436180C Immunoregulatory antibodies and uses thereof
11/08/2011	CA2422346C Dialysate of peritoneal dialysis and its preparation method
11/08/2011	CA2247285C Human tumor necrosis factor delta and epsilon
11/08/2011	CA2246352C Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
11/03/2011	WO2011136753A1 Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
11/03/2011	WO2011135743A1 Medicinal agent for prevention and/or treatment of hepatitis c
11/03/2011	WO2011135563A1 Metal entrapped bioactive composites
11/03/2011	WO2011134898A1 New combination therapy in treatment of oncological and fibrotic diseases
11/03/2011	WO2011134026A1 Cosmetic methods and compositions
11/03/2011	WO2011107653A3 Use of levodopa, carbidopa and entacapone for treating parkinson's disease
11/03/2011	WO2011088055A3 Methionine aminopeptidase 2 (metap2) inhibitors for treating cardiovascular or cerebrovascular disorders
11/03/2011	US20110270381 Methods and apparatus for stenting comprising enhanced embolic protection coupled with improved protections against restenosis and thrombus formation
11/03/2011	US20110269970 Phenethanolamine Derivatives for Treatment of Respiratory Diseases
11/03/2011	US20110269947 Apo-2 ligand/trail formulations
11/03/2011	US20110269852 Methods and mechanisms involving hyperpigmentation particularly for african american skin
11/03/2011	US20110269794 External Preparation for Athlete's Foot Treatment
11/03/2011	US20110269675 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
11/03/2011	US20110268725 Anti-NGF antibodies for the treatment of various disorders
11/03/2011	US20110268724 Methods and materials relating to cd84-like polypeptides and polynucleotides
11/03/2011	US20110268693 Compounds Having CRTH2 Antagonist Activity
11/03/2011	US20110265786 Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same
11/03/2011	CA2793616A1 New combination therapy in treatment of oncological and fibrotic diseases
11/02/2011	EP2383573A1 Screening method for substance useful as agent for treating prostate cancer
11/02/2011	EP2382992A1 Pharmaceutical composition for treating obesity or diabetes
11/02/2011	EP2382978A2 Modulation of the immune system by inositol phospholipids
11/02/2011	EP2381957A2 Therapeutic modulation of vaginal epithelium boundary lubrication
11/02/2011	EP2381956A1 Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
11/02/2011	EP2381955A1 Combination therapies using nap
11/02/2011	EP2381950A2 Compositions and methods of use
11/02/2011	EP2381942A1 Combination therapies for neoplastic disorders
11/02/2011	EP2381940A2 A new family of pain producing substances and methods to produce novel analgesic drugs
11/02/2011	EP2381935A1 Synergistic combinations of carotenoids and polyphenols
11/02/2011	EP2381920A2 Methods and compositions for treating p.acnes
11/02/2011	EP2381780A1 Compositions comprising decitabine and tetrahydrouridine and uses thereof
11/02/2011	EP2051710B1 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
11/02/2011	EP1615952B1 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
11/02/2011	EP1425389B1 Human antibodies specific for interleukin 15 (il-15)
11/02/2011	EP1386165B1 Inflammatory markers for detection and prevention of diabetes mellitus
11/02/2011	EP1299522B1 Alteration of cell membrane
11/02/2011	EP1212359B1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein
11/02/2011	CN102229994A Use of gene sequence associated with chronic hepatitis known as liver-stagnation in traditional Chinese medicine
11/02/2011	CN102229650A High purity lipopeptides, lipopeptide micelles and processes for preparing same
11/02/2011	CN102228692A Application of calcium channel blocker to preparation of medicament for antagonizing cardiotoxicity of medusocongestin
11/02/2011	CN102228691A Aspirin and anticoagulant pharmaceutical composition
11/02/2011	CN102228690A Application of antifolic in constructing mouse model with neural tube defects (NTDs)
11/02/2011	CN102228689A In vitro cancer therapy compound identification method
11/02/2011	CN101607086B Compound bismuth composition and preparation method thereof
11/01/2011	US8048926 L-DOPA amide derivatives and uses thereof
11/01/2011	US8048918 Treatment of hyperproliferative diseases
11/01/2011	US8048882 Pharmaceutical compositions with increased activity
11/01/2011	US8048873 Synergistic pharmaceutical combination for the prevention or treatment of diabetes
11/01/2011	US8048869 Estrogenic component comprising estetrol and estetrol-like substances, which has relatively low estrogenic potency, metabolic stability, long half-life; triene steroids; osteoporosis, arteriosclerosis, cognitive disturbances, Alzheimer's disease, peri- or post-menopausal disorders
11/01/2011	US8048852 Antimicrobial compounds and formulations
11/01/2011	US8048847 Derivatives of the IL-2 receptor gamma chain, their production and use
11/01/2011	US8048844 Preventing airway mucus production by administration of EGF-R antagonists
11/01/2011	US8048452 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor
11/01/2011	CA2517172C Therapeutic compositions
11/01/2011	CA2493208C Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
11/01/2011	CA2490351C Process for producing sustained-release composition
11/01/2011	CA2490254C Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
11/01/2011	CA2483750C Biologically active compounds for the modification of bodily odours
11/01/2011	CA2473461C Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
11/01/2011	CA2468826C Benzazole derivatives for the treatment of scleroderma
11/01/2011	CA2468254C Therapeutic coating for an intravascular implant
11/01/2011	CA2458534C Phenethanolamine derivatives for treatment of respiratory diseases
11/01/2011	CA2452986C Use of polyclonal anti-hiv goat serum as a therapeutic agent
11/01/2011	CA2439269C Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds
11/01/2011	CA2434526C Methods of administering epothilone analogs for the treatment of cancer
11/01/2011	CA2396718C Pre-transplant accomodated organs resistant to anti-donor immunity
11/01/2011	CA2374916C Diagnostics and therapeutics for cardiovascular disorders
11/01/2011	CA2203622C Compounds, pharmaceutical composition and diagnostic device comprising them and their use
11/01/2011	CA2105903C Methods and compositions for the detection of soluble .beta.-amyloid peptide
10/2011
10/27/2011	WO2011133177A1 Local anesthetic emulsion compositions and methods of making and using the same
10/27/2011	WO2011132177A1 Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them
10/27/2011	WO2011131926A1 Novel iminosugar combinations
10/27/2011	WO2011131445A1 Active ingredient combinations of magnolia bark extract and polyethoxylated compounds (peg-40 stearates)
10/27/2011	WO2011131441A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate)
10/27/2011	WO2011131439A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates
10/27/2011	WO2011075799A3 Oral antidepressant formulation
10/27/2011	WO2010121600A3 Particulate pharmaceutical composition having an opioid and an opioid antagonist
10/27/2011	US20110264696 Pharmaceutical Compositions and Methods for Verifying Dosing Compliance
10/27/2011	US20110263663 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
10/27/2011	US20110263638 Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker
10/27/2011	US20110263619 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
10/27/2011	US20110263568 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
10/27/2011	US20110263522 Antitumour compositions containing taxane derivatives
10/27/2011	US20110262538 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
10/27/2011	US20110262419 Specifically targeted catalytic antagonists and uses thereof
10/27/2011	CA2796592A1 Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them
10/27/2011	CA2794439A1 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment
10/27/2011	CA2794127A1 Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
10/26/2011	EP2380584A1 Immunostimulatory method
10/26/2011	EP2379561A2 Mlk inhibitors and methods of use
10/26/2011	EP2379174A1 Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
10/26/2011	EP2379173A1 Anti-snoring composition containing a thermogelling polymer
10/26/2011	EP2379113A1 Methods of treating tumor cells using rhcc protein, fragment or variant
10/26/2011	EP2379080A1 Pirenzepine as otoprotective agent

1 ... 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 ... 1151